Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Biolinerx Ltd ADR (BLRX)

Biolinerx Ltd ADR (BLRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
BioLineRx and Hemispherian AS to Present Data Demonstrating Strong Synergy of GLIX1 with PARP Inhibitors in HR-Proficient Ovarian Cancers at ESMO 2026 PR Newswire - Mon Jul 20, 6:00AM CDT

TEL AVIV, Israel and OSLO, Norway , July 20, 2026 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology...

BLRX : 2.76 (+2.22%)
BioLineRx and Hemispherian Announce New Preclinical Data Demonstrating Strong Synergistic Effect between GLIX1 and PARP Inhibitor in a Patient-Derived Ovarian Cancer Xenograft Model PR Newswire - Wed Jul 8, 6:00AM CDT

TEL AVIV, Israel and OSLO, Norway , July 8, 2026 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology...

BLRX : 2.76 (+2.22%)
BioLineRx Reports First Quarter 2026 Financial Results and Provides Corporate Update PR Newswire - Wed May 27, 6:00AM CDT

- Announced first patient dosed in Phase 1/2a clinical trial of GLIX1 for treatment of glioblastoma (GBM) -

BLRX : 2.76 (+2.22%)
BioLineRx and Hemispherian AS Highlight New Data on GLIX1 at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting PR Newswire - Fri May 22, 6:00AM CDT

TEL AVIV, Israel and OSLO, Norway , May 22, 2026 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology...

BLRX : 2.76 (+2.22%)
BioLineRx to Report First Quarter 2026 Results on May 27, 2026 PR Newswire - Wed May 20, 6:00AM CDT

Management to Hold Conference Call at 8:30 a.m. EDT

BLRX : 2.76 (+2.22%)
BioLineRx and Hemispherian Announce New GLIX1 Data Demonstrating Potent Anti-Tumor Effect in Glioblastoma (GBM) Across Multiple In-Vivo Studies, Including a Temozolomide (TMZ)-Resistant Model with Patient-Derived Xenografts PR Newswire - Tue May 19, 6:00AM CDT

New preclinical data further demonstrate GLIX1's robust efficacy in a dose-dependent manner, with strong anti-tumor activity observed even at the lowest doses tested

BLRX : 2.76 (+2.22%)
BioLineRx and Hemispherian Announce First Patient Dosed in Phase 1/2a Study of GLIX1 for the Treatment of Glioblastoma (GBM) PR Newswire - Tue Apr 28, 6:00AM CDT

Patient was dosed at NYU Langone Health under the supervision of Dr. Alexandra Miller, Chief of Neuro-Oncology & Co-Director of Brain and Spine Tumor Center, Perlmutter Cancer Center

BLRX : 2.76 (+2.22%)
BioLineRx Announces Initiation of Phase 1/2a Study of GLIX1 for the Treatment of Glioblastoma (GBM) PR Newswire - Thu Mar 26, 6:00AM CDT

GLIX1, a TET2 activator ,  is a first -in- class , oral, small molecule targeting DNA damage response in glioblastoma  and other cancers  

BLRX : 2.76 (+2.22%)
BioLineRx Reports 2025 Financial Results and Provides Corporate Update PR Newswire - Mon Mar 23, 6:00AM CDT

- On track to initiate Phase 1/2a clinical trial of GLIX1 for treatment of glioblastoma (GBM) by end of this month -

BLRX : 2.76 (+2.22%)
BioLineRx to Report 2025 Annual Results on March 23, 2026 PR Newswire - Mon Mar 16, 6:00AM CDT

Management to Hold Conference Call at 8:30 a.m. EDT

BLRX : 2.76 (+2.22%)

Barchart Exclusives

Anthropic Is Only Part of the Story. Cognizant Has a Much Bigger AI Plan. Barchart - 37 minutes ago
Cognizant is strengthening its AI consulting business by partnering across leading AI models, positioning itself to benefit regardless of which AI platform ultimately wins. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.